Manchester University NHS Foundation Trust (MFT) hospitals, including the Manchester Royal Infirmary(MRI), Wythenshawe Hospital and North Manchester General.
Dr Felton said: "Dexamethasone, which is a type of steroid used in a range of conditions – typically to reduce inflammation – is the first drug to improve survival rates in hospitalised coronavirus patients, which truly is a breakthrough."The short timeframe between our first MFT participant being recruited to the RECOVERY trial in March, to our first COVID-19 patient receiving dexamethasone as a standard NHS treatment in June, is an incredible turnaround."This could not have happened without patients consenting to take part in research – which is now directly benefitting all patients.